Embecta Corp. (EMBC)
NASDAQ • Healthcare
Last close at September 16, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Embecta Corp. keeps $8 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 24
in 69 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Embecta Corp. beat consensus on both revenue and adjusted EPS in the third fiscal quarter of 2026, reported Aug. 7, as revenue fell 8% to about $271.7 million from about $295.5 million a year ago. Revenue came in above the $254.5 million estimate by roughly 7%, while adjusted EPS of $0.56 topped the $0.27 consensus by about 111% and was down 50% from $1.12 a year earlier. Net income declined 54% to about $21.1 million from about $45.5 million a year ago, even as gross margin held near 52% and operating margin stayed around 18%. International remained the largest market at about $150.9 million, rising 12%, while U.S. revenue fell 25% to about $120.8 million. Operating cash flow was about $41.8 million, and the company repurchased about $3.9 million of stock and paid about $600,000 in dividends. Consensus for the next period calls for EPS of $0.34 on revenue of $283.6 million.
About Embecta Corp.
Embecta Corp. is a healthcare company focused on diabetes care, making injection products and related tools for people living with the disease. Listed on the NASDAQ as EMBC, Embecta sells pen needles, syringes, safety devices, and digital applications, and it generated $1.1 billion of revenue in FY2025.
Today's Snapshot
The day ended with EMBC 0.8% higher at 5.13, while its sector was flat. Trading was lighter than usual, with volume about two-thirds of its usual level.
Trading Volume
Below 10d avg (1.1M)
717.6K
vs S&P 500 Today
Outperforming Market
+1.37%
Updated: September 16, 2026 at 20:44 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$4.74 - $7.70Sell
- RSI (14)53.54Neutral
- Stochastic %K (14, 3, 3)31.83Neutral
- MACD Level (12, 26)0.18Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.